Le San Antonio Breast Cancer Symposium (SABCS) est un rendez-vous incontournable pour tous les experts internationaux dans le domaine du cancer du sein. Le congrès a lieu du 6 au 10 décembre 2022 à San Antonio au Texas et plusieurs études conduites par les équipes de chercheurs d’Unicancer seront présentées – notamment celles de l’intergroupe UCBG (French Breast Cancer Intergroupe Unicancer).

Poster discussion

SHARE
  • PD3-05. Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage breast cancer. Belkacémi Y et al., mecredi 7 décembre à 17h
PADA1 Transla
  • PD17-02. ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. Bailleux C et al., vendredi 9 décembre à 7h

Posters

TRAK-ER
  • OT1-01-01. A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER). Turner N et al., jeudi 6 décembre à 17h
INTERCEPT
  • OT1-10-01. Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after local therapy of isolated brain progression: InTTercePT, a UCBG/GINECO study. Bachelot T et al., jeudi 6 décembre à 17h
SHARE
  • P1-10-13. Economic comparison of standard external beam whole breast (WBI) versus accelerated partial breast irradiation (ABPI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. Le Bras A et al., jeudi 6 décembre à 17h
COMET
  • P1-03-04. Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab Guiu S et al., jeudi 6 décembre à 17h
UNIRAD
  • P2-02-07. Patients’ selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial. Giacchetti et al., mercredi 7 décembre à 7h
COMET
  • P4-07-24. Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer. Pierga JY et al., jeudi 8 décembre à 7h
COMET
  • P4-07-54. Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors. Billa O et al., jeudi 8 décembre à 7h

Contact presse
Daniela Barbieri
Contacter par email